Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity

Chemico-Biological Interactions

Volumn 148, Issue 1-2, 2004, Pages 37-48

  Marzano, Cristina ^a   Bettio, Frazia ^a   Baccichetti, Francarosa ^a   Trevisan, Andrea ^a   Giovagnini, Lorena ^a   Fregona, Dolores ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Antitumor activity; Cytogenetic damage; Nephrotoxicity; Platinum(II) complex

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; GLUTAMATE AMMONIA LIGASE; LIGAND; N ACETYL BETA GLUCOSAMINIDASE; PLATINUM COMPLEX; PYRIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; EHRLICH ASCITES TUMOR; ENZYME ACTIVITY; FEMALE; GENOTOXICITY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IC 50; MALE; MICRONUCLEUS; MICRONUCLEUS TEST; MOUSE; MOUSE STRAIN; NEPHROTOXICITY; NITROBLUE TETRAZOLIUM TEST; NONHUMAN; PERIPHERAL LYMPHOCYTE; PROTEIN URINE LEVEL; RAT; SISTER CHROMATID EXCHANGE; SOLID TUMOR; TUMOR VOLUME; URINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; HELA CELLS; HUMANS; INHIBITORY CONCENTRATION 50; KIDNEY; LYMPHOCYTES; MALE; MICE; MICRONUCLEUS TESTS; ORGANOPLATINUM COMPOUNDS; RATS; RATS, WISTAR; SISTER CHROMATID EXCHANGE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALIA; MAMMALIA; RATTUS NORVEGICUS;

EID: 3042656649     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2004.04.002     Document Type: Article

References (37)

1. B. Rosenberg, Platinum complexes for the treatment of cancer: why the search goes on, in: B. Lippert (Ed.), Cisplatin. Chemistry and Biochemistry of a Leading Anticancer Drug, Wiley-VCH, Basel, Switzerland, 1999, pp. 3-27.
2. Kelland L.R. New platinum antitumor complexes. Crit. Rev. Oncol./Hematol. 15:1993;191-219
3. Bodenner D.L., Dedon P.C., Keng P.C., Borch R. Effect of diethyldithiocarbamate on cis-diamminedichloroplatinum(II)-induced cytotoxicity, DNA cross-linking, and γ-glutamyl transpeptidase inhibition. Cancer Res. 46:1986;2745-2750
4. Dobyan D.C., Levi J., Jacobs C. Mechanism of cis-platinum nephrotoxicity. J. Pharmacol. Exp. Ther. 213:1980;515-556
5. Bruley-Rosset M., Vergnon I., Renoux G. Influences of sodium diethyldithiocarbamate, DTC (imuthiolR) on T cell defective responses of aged BALB/c mice. Int. J. Immunopharmacol. 8:1986;287-297
6. R.F. Borch, P.C. Dedon, A. Gringeri, T.J. Montine, Inhibition of platinum drug toxicity by diethyldithiocarbamate, in: M. Nicolini (Ed.), Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, Martinus Nijhoff, Boston, 1988, pp. 216-227.
7. Treskes M., Van-der-Vijgh W. JWR2721 as a modulator of cisplatin and carboplatin induced side effects in comparison with other chemoprotective agents: a molecular approach. Cancer Chemother. Pharmacol. 33:1993;93-106
8. Zunino F., Pratesi G., Micheloni A., Cavalletti E., Sala F., Tofanetti O. Protective effect of reduced glutathione against cisplatin-induced renal and systemic toxicity and its influence on the therapeutic activity of the antitumor drug. Chem. Biol. Interact. 70:1989;89-101
9. Borch R.F., Katz J.C., Lieder P.H., Pleasants M.E. Effect of diethyldithiocarbamate rescue on tumor response to cis-platinum in a rat mode. Proc. Natl. Acad. Sci. USA. 77:1980;5441-5444
10. Hidaka S., Tsuruoka M., Funakoshi T., Shimada H., Kiyozumi M., Kojima S. Protective effects of dithiocarbamates against renal toxicity of cis-diamminedichloroplatinum in rats. Ren Fail. 16:1994;337-349
11. Walker E.M., Schaefer R.F., Henle K.J., Schmidt B.J., Gale G.R., Cannon D.J., Jones M.M., Moss A.J. Combination and individual antitumor effects of hyperthermia, cisplatin, and selected dithiocarbamates. Ann-Clin-Lab-Sci. 19:1989;242-254
12. Kelland L.R., Sharp S.Y., O'Neill C.F., Raynaud F.I., Beale P.J., Judson I.R. Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance. J. Inorg. Biochem. 77:1999;111-115
13. Kelland L.R. in: Proceedings of the Eighth International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. J. Inorg. Biochem. 77:1999;0121-124
14. Faraglia G., Fregona D., Sitran S., Giovagnini L., Marzano C., Baccichetti F., Casellato U., Graziani R. Platinum(II) and palladium(II) complexes with dithicarbamates and amines: synthesis, characterization and cell assay. J. Inorg. Biochem. 83:2001;31-40
15. Marzano C., Fregona D., Baccichetti F., Trevisan A., Giovagnini L., Bordin F. Cytotoxicity and DNA damage induced by a new platinum(II) complex with pyridine and dithiocarbamate. Chem. Biol. Interact. 140:2002;215-229
16. Marzano C., Trevisan A., Giovagnini L., Fregona D. Synthesis of a new platinum(II)complex: anticancer activity and nephrotoxicity in vitro. Toxicol Vitro. 16:2002;413-419
17. Lanzi C., Perego P., Supino R., Romanelli S., Pensa T., Carenini N., Viano I., Colangelo D., Leone R., Apostoli P., Cassinelli G., Gambetta R.A., Zunino F. Decreased drug accumulation and increased tolerance to DNA damage in tumor cells with a low level of cisplatin resistance. Biochem. Pharmacol. 55:1998;1247-1254
18. Perego P., Caserini C., Gatti L., Carenini N., Romanelli S., Supino R., Colangelo D., Viano I., Leone R., Spinelli S., Pezzoni G., Manzotti C., Farrell N., Zunino F. A novel trinuclear platinum complex overcomes cisplatin resistance in an osteosarcoma cell system. Mol. Pharmacol. 55:1999;528-534
19. Sanderson B.J.S., Ferguson L.R., Denny W.A. Mutagenic and carcinogenic properties of platinum-based anticancer drugs. Mutat. Res. 355:1996;59-70
20. Carrano A.V., Thompson L.H., Lindl P.A., Minkler J.L. Sister chromatid exchange as an indicator of mutagenesis. Nature. 271:1978;551-553
21. Fenech M., Morley A.A. Measurement of micronuclei in lymphocytes. Mutat. Res. 147:1985;29-36
22. Ferlin M.G., Marzano C., Chiarelotto G., Baccichetti F., Bordin F. Synthesis and antiproliferative activity of some variously substituted acridine and azacridine derivatives. Eur. J. Med. Chem. 35:2000;827-837
23. Trevisan A., Marzano C., Cristofori P., Borella-Venturini M., Giovagnini L., Fregona D. Synthesis of a palladium(II)-dithiocarbamate complex: biological assay and nephrotoxicity in rats. Arch. Toxicol. 76:2002;262-268
24. Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 48:1988;589-601
25. Perez J.M., Navarro-Ranninger M.C., Requena J.M., Jimenez-Ruiz A., Parrondo E., Craciunescu D., Lopez M.C., Alonso C. DNA binding properties and antileukemic (L1210) activity of a Pt-pentamidine complex. Chem. Biol. Interact. 77:1991;341-355
26. Marverti G., Andrews P.A., Piccinini G., Ghiaroni S., Barbieri D., Moruzzi M.S. Modulation of cis-diamminedichloroplatinum(II) accumulation and cytotoxicity by spermine in sensitive and resistant human ovarian carcinoma cells. Eur. J. Cancer. 33:1997;669-675
27. Kelland L.R., Barnard C.F., Mellish K.J., Jones M., Goddard P.M., Valenti M., Bryant A., Murrer B.A., Harrap K.R. A novel trans-platinum coordination complex possessing in vitro and in vivo antitumor activity. Cancer Res. 54:1994;5618-5622
28. Wiencke J.K., Cervenka J., Paulus H. Mutagenic activity of anticancer agent cis-dichlorodiammine platinum-II. Mutat. Res. 68:1979;69-77
29. Trevisan A., Giraldo M., Borella M., Bottegal S., Fabrello A. Tubular segment-specific biomarkers of nephrotoxicity in the rat. Toxicol. Lett. 124:2001;113-120
30. Jamieson E.R., Lippard S. Structure, recognition, and processing of cisplatin-DNA adducts. Chem. Rev. 99:1999;2467-2498
31. Marzano C., Baccichetti F., Carlassare F., Chilin A., Lora S., Bordin F. DNA damage induced by 4, 6, 8, 9-tetramethyl-2H-furo[2, 3-h]quinolin-2-one, a new furocoumarin analog: biological consequences. Photochem. Photobiol. 71:2000;263-272
32. Snyder R.D., Green J.W. A review of the genotoxicity of marketed pharmaceuticals. Mutat. Res. 488:2001;151-169
33. Goldstein R.S., Mayor G.H. Minireview. The nephrotoxicity of cisplatin. Life Sci. 32:1983;685-690
34. Hanigan M.H., Gallagher B.C., Taylor P.T. Jr., Large M.K. Inhibition of gamma-glutamyl transpeptidase activity by acivicin in vivo protects the kidney from cisplatin-induced toxicity. Cancer Res. 54:1994;5925-5929
35. Hannemann J., Baumann K. Nephrotoxicity of cisplatin, carboplatin and transplatin. A comparative in vitro study. Arch Toxicol. 64:1990;393-400
36. Zhang J.G., Lindup W.E. Cisplatin-induced nephrotoxicity in vitro: increases in cytosolic calcium concentration and the inhibition of cytosolic and mitochondrial protein kinase C. Toxicol. Lett. 89:1996;11-17
37. Jones M.M., Basinger M.A., Craft W.D., Domingo J.L., Llobet J.M. Control of some aspects of cis-platinum nephrotoxicity. Arch Toxicol. 59:1986;167-171